Wells Fargo Upgrades Becton, Dickinson to Overweight, Announces $275 Price Target
Wells Fargo analyst Lawrence Biegelsen upgrades Becton, Dickinson (NYSE:BDX) from Equal-Weight to Overweight and announces $275 price target.
What It Means For US Stocks To Be In A Bear Market
Wall Street has officially fallen into a bear market as investor sentiment is hammered by soaring inflation, rising interest rates and worries about a looming recession in the world’s largest economy.
Here’s How Much You Would Have Made Owning Becton, Dickinson Stock In The Last 20 Years
Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 20 years by 3.34% on an annualized basis producing an average annual return of 10.37%. Currently, Becton, Dickinson has a market capitalization of $71.95 billion.
$1000 Invested In Becton, Dickinson 10 Years Ago Would Be Worth This Much
Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 10 years by 1.48% on an annualized basis producing an average annual return of 13.59%. Currently, Becton, Dickinson has a market capitalization of $72.68 billion.
BD, Mitsubishi Gas Chemical Have Signed A Letter Of Intent To Discuss A Partnership Agreement To Explore New Ways To Advance Biologic Drug Delivery
https://news.bd.com/2022-05-18-BD-and-Mitsubishi-Gas-Chemical-have-signed-a-letter-of-intent-LOI-to-discuss-a-partnership-agreement-to-explore-new-ways-to-advance-biologic-drug-delivery
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Morgan Stanley Maintains Overweight on Becton, Dickinson, Raises Price Target to $295
Morgan Stanley maintains Becton, Dickinson (NYSE:BDX) with a Overweight and raises the price target from $293 to $295.
Expert Ratings For Becton, Dickinson
Analysts have provided the following ratings for Becton, Dickinson (NYSE:BDX) within the last quarter:
Morgan Stanley Maintains Overweight on Becton, Dickinson, Lowers Price Target to $293
Morgan Stanley analyst David Lewis maintains Becton, Dickinson (NYSE:BDX) with a Overweight and lowers the price target from $310 to $293.
BD Collaborates With ReturnSafe To Help Employers Manage COVID-19 Testing
BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee health, safety and